BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37734445)

  • 1. Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer.
    Liu F; Ververs JD; Farris MK; Blackstock AW; Munley MT
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):829-838. PubMed ID: 37734445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma.
    Liu F; Brown DR; Munley MT
    Radiother Oncol; 2024 May; 194():110223. PubMed ID: 38467342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.
    Liu F; Farris MK; Ververs JD; Hughes RT; Munley MT
    Radiother Oncol; 2024 Jun; 195():110257. PubMed ID: 38548113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group.
    Ohri N; Werner-Wasik M; Grills IS; Belderbos J; Hope A; Yan D; Kestin LL; Guckenberger M; Sonke JJ; Bissonnette JP; Xiao Y
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e379-84. PubMed ID: 22999272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.
    Liu F; Tai A; Lee P; Biswas T; Ding GX; El Naqa I; Grimm J; Jackson A; Kong FS; LaCouture T; Loo B; Miften M; Solberg T; Li XA
    Radiother Oncol; 2017 Feb; 122(2):286-294. PubMed ID: 27871671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
    Lee P; Loo BW; Biswas T; Ding GX; El Naqa IM; Jackson A; Kong FM; LaCouture T; Miften M; Solberg T; Tome WA; Tai A; Yorke E; Li XA
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):160-171. PubMed ID: 30954520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
    Royce TJ; Mavroidis P; Wang K; Falchook AD; Sheets NC; Fuller DB; Collins SP; El Naqa I; Song DY; Ding GX; Nahum AE; Jackson A; Grimm J; Yorke E; Chen RC
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):227-236. PubMed ID: 32900561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
    Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
    von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
    Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.
    Liang X; Penagaricano J; Zheng D; Morrill S; Zhang X; Corry P; Griffin RJ; Han EY; Hardee M; Ratanatharathom V
    Radiat Oncol; 2016 Jan; 11():10. PubMed ID: 26800883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal dose and fraction number in SBRT of lung tumours: A radiobiological analysis.
    Ruggieri R; Stavrev P; Naccarato S; Stavreva N; Alongi F; Nahum AE
    Phys Med; 2017 Dec; 44():188-195. PubMed ID: 28130055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of tumor control probability of stereotactic body radiation therapy for lung cancer with a regrowth model.
    Tai A; Liu F; Gore E; Li XA
    Phys Med Biol; 2016 May; 61(10):3903-13. PubMed ID: 27117498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer.
    Mahadevan A; Moningi S; Grimm J; Li XA; Forster KM; Palta M; Prior P; Goodman KA; Narang A; Heron DE; Lo SS; Urbanic J; Herman JM
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):206-216. PubMed ID: 33358561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.
    Lu JY; Lin PX; Huang BT
    Radiat Oncol; 2019 Jun; 14(1):111. PubMed ID: 31221159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
    Steber CR; Hughes RT; Soike MH; Jacobson T; Helis CA; Farris JC; Farris MK
    Clin Lung Cancer; 2021 Jan; 22(1):e122-e131. PubMed ID: 33046359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
    Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
    Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.
    Repka MC; Aghdam N; Kataria SK; Campbell L; Suy S; Collins SP; Anderson E; Lischalk JW; Collins BT
    Radiat Oncol; 2017 Oct; 12(1):162. PubMed ID: 29052514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
    Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell Lung Cancer.
    Stephans KL; Woody NM; Reddy CA; Varley M; Magnelli A; Zhuang T; Qi P; Videtic GMM
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):462-469. PubMed ID: 29353658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiation therapy for stage I non-small cell lung cancer: The importance of treatment planning algorithm and evaluation of a tumor control probability model.
    Ohri N; Tomé W; Kalnicki S; Garg M
    Pract Radiat Oncol; 2018; 8(2):e33-e39. PubMed ID: 29233523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.